The Oncology Brothers and Sumanta Kumar Pal, MD, FASCO, offer comprehensive insights on the treatment of patients with metastatic kidney cancer.
Pembrolizumab Prolongs Survival in Clear-Cell RCC
Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.
Oncology On-The-Go Podcast: Integrative and Palliative Kidney Cancer Care
Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.
Stereotactic Radiation Appears Effective in Primary Renal Cell Cancer
Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.
OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC
In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.
Belzutifan Improves QoL and Disease Progression Time in Advanced Kidney Cancer
Treatment with belzutifan increased the time to disease progression, according to findings from the LITESPARK-005 trial.
Subcutaneous Nivolumab Demonstrates Noninferiority to Standard IV Dosing in ccRCC
Findings from the phase 3 CheckMate 67T trial showed noninferiority of subcutaneous nivolumab when compared with intravenous nivolumab.